Taken together, our results suggest that resveratrol suppresses mTORC1 signaling in androgen-independent prostate cancer cells by directly targeting DDX5 (Figure 7), and 10 other resveratrol-binding proteins might also be druggable targets, similar to DDX5. This evidence concerns the gene DDX5 and Familial prostate cancer.